Abstract
Cyclosporine A (CsA) is the immunosuppressant of first choice in allotransplantation. Its use is associated with side effects of nephrotoxicity and neurotoxicity, which are among the most prominent. This study was undertaken to explore whether expression and activity of heme oxygenase (HO), the rate-limiting enzyme in heme degradation, is altered in a rat model of CsA-induced injury. Male Sprague Dawley rats were divided into four groups and treated for 21 days. Group I (control) was injected with olive oil (vehicle), group II with CsA (15 mg/kg/day), group III with CsA and the HO inhibitor stannous mesoporphyrin (SnMP) (30 mmol/kg/day) and group IV with one dose of the HO inducer cobalt protoporphyrin (CoPP) 5 mg/100 or heme (10 mg/kg body weight), three days after onset of CsA treatment. Renal tissue was processed for light microscopy, and for HO-1 enzyme activity, assay and for Western blot analysis. In CsA-treated rats there was histological evidence of tubulointerstitial scarring. HO-1 was undetectable in CsA-treated rats compared to control while there was no change in HO-2. In animals treated with a combination of CsA and SnMP, HO-1 activity was further reduced. In animals treated with a combination of CsA and CoPP, HO-1 protein levels were partially restored. These observations indicate that downregulation of HO-1 expression by CsA could be one mechanism underlying CsAinduced toxicity. The CsA-induced decrease in HO-1 expression is partial and restorable, and attempts to preserve HO levels may attenuate CsA toxicity.
Keywords: cyclosporine a, heme oxygenase, nephrotoxicity, neurotoxicity
Current Neurovascular Research
Title: Protective Effects of Heme-Oxygenase Expression in Cyclosporine A - Induced Injury
Volume: 2 Issue: 2
Author(s): Rita Rezzani, Luigi Rodella, Rossella Bianchi, Alvin I. Goodman and Elias A. Lianos
Affiliation:
Keywords: cyclosporine a, heme oxygenase, nephrotoxicity, neurotoxicity
Abstract: Cyclosporine A (CsA) is the immunosuppressant of first choice in allotransplantation. Its use is associated with side effects of nephrotoxicity and neurotoxicity, which are among the most prominent. This study was undertaken to explore whether expression and activity of heme oxygenase (HO), the rate-limiting enzyme in heme degradation, is altered in a rat model of CsA-induced injury. Male Sprague Dawley rats were divided into four groups and treated for 21 days. Group I (control) was injected with olive oil (vehicle), group II with CsA (15 mg/kg/day), group III with CsA and the HO inhibitor stannous mesoporphyrin (SnMP) (30 mmol/kg/day) and group IV with one dose of the HO inducer cobalt protoporphyrin (CoPP) 5 mg/100 or heme (10 mg/kg body weight), three days after onset of CsA treatment. Renal tissue was processed for light microscopy, and for HO-1 enzyme activity, assay and for Western blot analysis. In CsA-treated rats there was histological evidence of tubulointerstitial scarring. HO-1 was undetectable in CsA-treated rats compared to control while there was no change in HO-2. In animals treated with a combination of CsA and SnMP, HO-1 activity was further reduced. In animals treated with a combination of CsA and CoPP, HO-1 protein levels were partially restored. These observations indicate that downregulation of HO-1 expression by CsA could be one mechanism underlying CsAinduced toxicity. The CsA-induced decrease in HO-1 expression is partial and restorable, and attempts to preserve HO levels may attenuate CsA toxicity.
Export Options
About this article
Cite this article as:
Rezzani Rita, Rodella Luigi, Bianchi Rossella, Goodman I. Alvin and Lianos A. Elias, Protective Effects of Heme-Oxygenase Expression in Cyclosporine A - Induced Injury, Current Neurovascular Research 2005; 2 (2) . https://dx.doi.org/10.2174/1567202053586730
DOI https://dx.doi.org/10.2174/1567202053586730 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Update of the Published Reports on Biologics Use for Psoriasis and the Reimbursement Status in Asia-Pacific Region
Current Rheumatology Reviews Targeting Cytokines, Chemokines and Adhesion Molecules in Rheumatoid Arthritis
Current Rheumatology Reviews Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety Aging and DNA Methylation
Current Chemical Biology Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population
Current Alzheimer Research Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective
Current Rheumatology Reviews Current Treatment of Autoimmune Blistering Diseases
Current Drug Discovery Technologies Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?
Current Cancer Drug Targets HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Mouse Models of Familial Hemiplegic Migraine for Studying Migraine Pathophysiology
Current Neuropharmacology Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment
Current Cancer Therapy Reviews The Pathology Induced by Highly Active Antiretroviral Therapy Against Human Immunodeficiency Virus: an Update
Current Medicinal Chemistry Cerebral Amyloid Angiopathy: A Common Cause of Cerebral Hemorrhage
Current Medicinal Chemistry The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology Nuclear Magnetic Resonance Spectroscopy and Genetic Disorders
Current Medicinal Chemistry Herpes Simplex Encephalitis: From Virus to Therapy
Infectious Disorders - Drug Targets Persistent Psychosis from Toluene Exposure; More Likely Coincidence than Cause: A Review of our Experience and the Literature
Current Psychiatry Reviews Plasmodium Drug Targets Outside the Genetic Control of the Parasite
Current Pharmaceutical Design The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Current Clinical Pharmacology Tryptamine Induces Axonopathy and Mitochondriopathy Mimicking Neurodegenerative Diseases via Tryptophanyl-tRNA Deficiency
Current Alzheimer Research